Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

[1]  R. Bouabdallah,et al.  Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft‐versus‐host disease in reduced‐intensity conditioning transplantation for hematologic diseases , 2013, Cancer.

[2]  P. Chevallier,et al.  Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced‐intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo‐SCT) , 2013, European journal of haematology.

[3]  D. Blaise,et al.  Randomized study of 2 reduced‐intensity conditioning strategies for human leukocyte antigen‐matched, related allogeneic peripheral blood stem cell transplantation , 2013, Cancer.

[4]  J. Wagner,et al.  Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. , 2013, Blood.

[5]  D. Blaise,et al.  Do different conditioning regimens really make a difference? , 2012, Hematology. American Society of Hematology. Education Program.

[6]  D. Blaise,et al.  Does antithymocyte globulin have a place in reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation? , 2012, Hematology. American Society of Hematology. Education Program.

[7]  K. Ballen,et al.  Improving outcomes in umbilical cord blood transplantation: state of the art. , 2012, Blood reviews.

[8]  J. Ritz,et al.  Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  A. Velardi,et al.  The EBMT activity survey: 1990–2010 , 2012, Bone Marrow Transplantation.

[10]  J. Wagner,et al.  Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors , 2012, Bone Marrow Transplantation.

[11]  P. Chevallier,et al.  Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. , 2012, Blood.

[12]  A. Scaradavou,et al.  Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation , 2012, Proceedings of the National Academy of Sciences.

[13]  J. Wagner,et al.  Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. , 2010, Blood.

[14]  E. Gluckman,et al.  An overview of the progress on double umbilical cord blood transplantation , 2011, Haematologica.

[15]  J. Ritz,et al.  Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis , 2011, Bone Marrow Transplantation.

[16]  A. Scaradavou,et al.  How I treat: the selection and acquisition of unrelated cord blood grafts. , 2011, Blood.

[17]  P. Szabolcs.  The immunobiology of cord blood transplantation , 2010, The Korean journal of hematology.

[18]  M. Labopin,et al.  Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT In Adults with Acute Leukemia In Remission. An Eurocord and ALWP Collaboration Study , 2010 .

[19]  M. Mohty,et al.  Advances in umbilical cord transplantation: the role of thymoglobulin/ATG in cord blood transplantation. , 2010, Best practice & research. Clinical haematology.

[20]  P. Chevallier,et al.  Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors , 2010, Bone Marrow Transplantation.

[21]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  J. Wagner,et al.  Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. , 2009, Blood.

[23]  J. Wagner,et al.  Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Blaise,et al.  Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens , 2008, Bone Marrow Transplantation.

[25]  J. Bourhis,et al.  Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. , 2008, Experimental hematology.

[26]  Avis J. Thomas,et al.  Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  J. Wagner,et al.  Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. , 2007, Blood.

[28]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Blaise,et al.  Reduced Intensity Conditioning Regimen in Single Unrelated Cord Blood Transplantation in Adults with Hematological Malignant Disorders. An Eurocord-Netcord and SFGM-TC Survey. , 2006 .

[30]  J. Wagner,et al.  Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. , 2006, Blood.

[31]  J. Wagner,et al.  Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. , 2006, Blood.

[32]  J. Wagner,et al.  Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. , 2004, The New England journal of medicine.

[33]  M. Labopin,et al.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. , 2004, The New England journal of medicine.

[34]  D. Blaise,et al.  Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation , 2004, Bone Marrow Transplantation.

[35]  J. Wagner,et al.  Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. , 2003, Blood.

[36]  S. Karandish,et al.  Double‐chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units , 2002, British journal of haematology.

[37]  P. Suess,et al.  Comparison of short tandem repeat and variable number tandem repeat genetic markers for quantitative determination of allogeneic bone marrow transplant engraftment , 2002, Bone Marrow Transplantation.

[38]  J. Wagner,et al.  Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. , 2001, The New England journal of medicine.

[39]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[40]  D. Higby,et al.  Transplantation of unrelated cord blood cells , 1998, Bone Marrow Transplantation.

[41]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[42]  Zhang Hq,et al.  Unrelated, HLA-mismatched multiple human umbilical cord blood transfusion in four cases with advanced solid tumors: initial studies. , 1994 .

[43]  J. Kurtzberg,et al.  Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. , 1989, The New England journal of medicine.

[44]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[45]  E. Thiel,et al.  Myeloid membrane markers. I. Expression of marker antigens specific for murine granulocytes and their precursor cells. , 1977, Experimental hematology.

[46]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.